Abstract

No survival improvement in patients with high-risk multiple myeloma harbouring del(17p) and/or t(4;14) over the two past decades.

Full Text
Published version (Free)

Talk to us

Join us for a 30 min session where you can share your feedback and ask us any queries you have

Schedule a call

Similar Papers

Paper Title
Journal
Date
Author
Long-Term Carfilzomib for High-Risk Patients with Newly Diagnosed Multiple Myeloma: A Pooled Analysis of Two Phase 1/2 Studies
Stelvio Ballanti ... Vittorio Montefusco
Blood | VOL. 132
Stelvio Ballanti, et. al.Stelvio Ballanti ... Vittorio Montefusco
29 Nov 2018
Outcomes of Tandem Hematopoietic Stem Cell Autologous Transplant in High-Risk Myeloma Patients: A Single-Center Experience
Shona Philip ... Uday Deotare
Blood | VOL. 138
Shona Philip, et. al.Shona Philip ... Uday Deotare
05 Nov 2021
Clinical Course of High-Risk Multiple Myeloma Patients in Korea: A Multicenter Retrospective Study
Hyeonseok Eom ... Misun Park
Blood | VOL. 136
Hyeonseok Eom, et. al.Hyeonseok Eom ... Misun Park
05 Nov 2020
Improved survival in multiple Myeloma patients undergoing autologous stem cell transplantation is entirely in the standard cytogenetic risk groups
Vincent Luong ... Evren Alici
European Journal of Haematology | VOL. 106
Vincent Luong, et. al.Vincent Luong ... Evren Alici
02 Feb 2021
View more papers

More From: British journal of haematology

Paper Title
Journal
Date
Author
Tyrosine kinase inhibitor maintenance following chimeric antigen receptor T-cell therapy in Philadelphia chromosome-positive acute lymphoblastic leukaemia.
Tamer Othman ... Ibrahim Aldoss
British journal of haematology | VOL. -
Tamer Othman, et. al.Tamer Othman ... Ibrahim Aldoss
29 May 2024
Haematopoietic stem cell transplantation after reduced intensity conditioning in children and adolescents with chronic myeloid leukaemia: A prospective multicentre trial of the I-BFM Study Group.
Herbert Pichler ... Adriana Balduzzi
British journal of haematology | VOL. -
Herbert Pichler, et. al.Herbert Pichler ... Adriana Balduzzi
27 May 2024
Canadian cancer trials group LY.17: A randomized phase II study evaluating novel salvage therapy pre-autologous stem cell transplant in relapsed/refractory diffuse large B-cell lymphoma-outcome of rituximab-dose-intensive cyclophosphamide, etoposide, cisplatin (R-DICEP) versus R-GDP.
Douglas A Stewart ... Michael Crump
British journal of haematology | VOL. -
Douglas A Stewart, et. al.Douglas A Stewart ... Michael Crump
27 May 2024
RUNX1::ETO and CBFβ::MYH11 converge on aberrant activation of BCAT1 to confer a therapeutic vulnerability in core-binding factor-acute myeloid leukaemia.
Siyang Wang ... Kankan Wang
British journal of haematology | VOL. -
Siyang Wang, et. al.Siyang Wang ... Kankan Wang
27 May 2024
View more papers